Common reduction of the Raf kinase inhibitory protein in clear cell renal cell carcinoma

Oncotarget

Volumn 5, Issue 17, 2014, Pages 7406-7419

  Hill, Brianne ^a,b,c   de Melo, Jason ^a,b,c   Yan, Judy ^a,b,c   Kapoor, Anil ^a,c   He, Lizhi ^a,b,c,d   Cutz, Jean Claude ^a   Feng, Xingchang ^a,c,e   Bakhtyar, Nazihah ^a,b,c   Tang, Damu ^a,b,c  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c ST JOSEPH S HOSPITAL   (Canada)

^d HARVARD MEDICAL SCHOOL   (United States)

^e NORTHEAST AGRICULTURAL UNIVERSITY   (China)

Author keywords

ccRCC; ERK; Kidney cancer; Raf; RKIP

Indexed keywords

MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; NERVE CELL ADHESION MOLECULE; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; SHORT HAIRPIN RNA; VASCULOTROPIN A; VIMENTIN; VON HIPPEL LINDAU PROTEIN; PEBP1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER INHIBITION; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; METASTASIS; MICROARRAY ANALYSIS; MOUSE; NOD SCID MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; PROTEIN REDUCTION; QUANTITATIVE ANALYSIS; RENAL CANCER CELL LINE; RKIP GENE; SURVIVAL RATE; TRANSCRIPTION REGULATION; TUMOR INVASION; TUMOR XENOGRAFT; TWO DIMENSIONAL GEL ELECTROPHORESIS; VHL GENE; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; DNA MICROARRAY; ENZYMOLOGY; KIDNEY TUMOR; MASS SPECTROMETRY; NONOBESE DIABETIC MOUSE; REAL TIME POLYMERASE CHAIN REACTION; SCID MOUSE; TUMOR SUPPRESSOR GENE; XENOGRAFT;

ANIMALS; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; GENES, TUMOR SUPPRESSOR; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MASS SPECTROMETRY; MICE; MICE, INBRED NOD; MICE, SCID; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84907520759     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1558     Document Type: Article

References (58)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58:71-96.
2. Cohen HT and McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005; 353:2477-2490.
3. Lopez-Beltran A, Scarpelli M, Montironi R and Kirkali Z. 2004 WHO classification of the renal tumors of the adults. Eur Urol. 2006; 49:798-805.
4. Kaelin WG Jr. Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein. Cancer. 2009; 115:2262-2272.
5. Walther MM, Lubensky IA, Venzon D, Zbar B and Linehan WM. Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications. J Urol. 1995; 154:2010-2014.
6. Shuin T, Kondo K, Torigoe S, Kishida T, Kubota Y, Hosaka M, Nagashima Y, Kitamura H, Latif F, Zbar B, Lerman MI and Yao M. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res. 1994; 54:2852-2855.
7. Clifford SC, Prowse AH, Affara NA, Buys CH and Maher ER. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer. 1998; 22:200-209.
8. Nickerson ML, Jaeger E, Shi Y, Durocher JA, Mahurkar S, Zaridze D. Matveev V, Janout V, Kollarova H, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, Mukeria A, Holcatova I and Schmidt LS, et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res. 2008; 14:4726-34.
9. Neumann HP and Zbar B. Renal cysts, renal cancer and von Hippel-Lindau disease. Kidney Int. 1997; 51:16-26.
10. Rankin EB, Tomaszewski JE and Haase VH. Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor. Cancer Res. 2006; 66:2576-83.
11. Klysik J, Theroux SJ, Sedivy JM, Moffit JS and Boekelheide K. Signaling crossroads: the function of Raf kinase inhibitory protein in cancer, the central nervous system and reproduction. Cell Signal. 2008; 20:1-9.
12. Escara-Wilke J, Yeung K and Keller ET. Raf kinase inhibitor protein (RKIP) in cancer. Cancer Metastasis Rev. 2012; 31:615-20.
13. Park S, Rath O, Beach S, Xiang X, Kelly SM, Luo Z, Kolch W and Yeung KC. Regulation of RKIP binding to the N-region of the Raf-1 kinase. FEBS Lett. 2006; 580: 6405-6412.
14. Yeung K, Janosch P, McFerran B, Rose DW, Mischak H, Sedivy JM and Kolch W. Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein. Mol Cell Biol. 2000; 20:3079-3085.
15. Trakul N, Menard RE, Schade GR, Qian Z and Rosner MR. Raf kinase inhibitory protein regulates Raf-1 but not B-Raf kinase activation. J Biol Chem. 2005; 280:24931-24940.
16. King AJ, Sun H, Diaz B, Barnard D, Miao W, Bagrodia S and Marshall MS. The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338. Nature. 1998; 396:180-183.
17. Fabian JR, Daar IO and Morrison DK. Critical tyrosine residues regulate the enzymatic and biological activity of Raf-1 kinase. Mol Cell Biol. 1993; 13:7170-7179.
18. Corbit KC, Trakul N, Eves EM, Diaz B, Marshall M and Rosner MR. Activation of Raf-1 signaling by protein kinase C through a mechanism involving Raf kinase inhibitory protein. J Biol Chem. 2003; 278:13061-13068.
19. Al-Mulla F, Bitar MS, Al-Maghrebi M, Behbehani AI, Al-Ali W, Rath O, Doyle B, Tan KY, Pitt A and Kolch W. Raf kinase inhibitor protein RKIP enhances signaling by glycogen synthase kinase-3β. Cancer Res. 2011; 71:1334-43.
20. Yeung KC, Rose DW, Dhillon AS, Yaros D, Gustafsson M, Chatterjee D, McFerran B, Wyche J, Kolch W and Sedivy JM. Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation. Mol Cell Biol. 2001; 21:7207-7217.
21. Katsman A, Umezawa K and Bonavida B. Chemosensitization and immunosensitization of resistant cancer cells to apoptosis and inhibition of metastasis by the specific NF-kappaB inhibitor DHMEQ. Curr Pharm Des. 2009; 15:792-808.
22. Wu K and Bonavida B. The activated NF-kappaB-Snail-RKIP circuitry in cancer regulates both the metastatic cascade and resistance to apoptosis by cytotoxic drugs. Crit Rev Immunol. 2009; 29:241-54.
23. Guarino M, Rubino B and Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology. 2007; 39:305-318.
24. Yilmaz M and Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009; 28:15-33.
25. Ren G, Baritaki S, Marathe H, Feng J, Park S, Beach S, Bazeley PS, Beshir AB, Fenteany G, Mehra R, Daignault S, Al-Mulla F, Keller E, Bonavida B, de la Serna I and Yeung KC. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. Cancer Res. 2012; 72:3091-104.
26. Fu Z, Smith PC, Zhang L, Rubin MA, Dunn RL, Yao Z and Keller ET. Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst. 2003; 95:878-89.
27. Keller ET, Fu Z and Brennan M. The biology of a prostate cancer metastasis suppressor protein: Raf kinase inhibitor protein. J Cell Biochem. 2005; 94:273-278.
28. Chatterjee D, Bai Y, Wang Z, Beach S, Mott S, Roy R, Braastad C, Sun Y, Mukhopadhyay A, Aggarwal BB, Darnowski J, Pantazis P, Wyche J, Fu Z, Kitagwa Y and Keller ET, et al. RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. J Biol Chem. 2004; 279:17515-17523.
29. Hagan S, Al-Mulla F, Mallon E, Oien K, Ferrier R, Gusterson B, García JJ and Kolch W. Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis. Clin Cancer Res. 2005; 11:7392-7397.
30. Schuierer MM, Bataille F, Hagan S, Kolch W and Bosserhoff AK. Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Res. 2004; 64:5186-5192.
31. Al-Mulla F, Hagan S, Behbehani AI, Bitar MS, George SS, Going JJ, García JJ, Scott L, Fyfe N, Murray GI and Kolch W. Raf kinase inhibitor protein expression in a survival analysis of colorectal cancer patients. J Clin Oncol. 2006; 24:5672-5679.
32. Martinho O, Gouveia A, Silva P, Pimenta A, Reis RM and Lopes JM. Loss of RKIP expression is associated with poor survival in GISTs. Virchows Arch. 2009; 455:277-284.
33. Maher ER and Kaelin WG Jr. von Hippel-Lindau disease. Medicine. 1997; 76:381-91.
34. Choyke PL, Glenn GM, Walther MM, Zbar B and Linehan WM. Hereditary renal cancers. Radiology. 2003; 226:33-46.
35. Beroukhim R, Brunet J-P, Di Napoli A, Mertz KD, Seeley A, Pires MM, Linhart D, Worrell RA, Moch H, Rubin MA, Sellers WR, Meyerson M, Linehan WM, Kaelin WG and Signoretti S. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res. 2009; 69:4674-81.
36. Gumz ML, Zou H, Kreinest PA, Childs AC, Belmonte LS, LeGrand SN, Wu KJ, Luxon BA, Sinha M, Parker AS, Sun L-Z, Ahlquist DA, Wood CG and Copland JA. Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Res. 2007; 13:4740-9.
37. Higgins JPT, Shinghal R, Gill H, Reese JH, Terris M, Cohen RJ, Fero M, Pollack JR, van de Rijn M and Brooks JD. Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. The American journal of pathology. 2003; 162:925-32.
38. Jones J, Otu H, Spentzos D, Kolia S, Inan M, Beecken WD, Fellbaum C, Gu X, Joseph M, Pantuck AJ, Jonas D and Libermann TA. Gene signatures of progression and metastasis in renal cell cancer. Clinical Cancer Res. 2005; 11:5730-9.
39. Lenburg ME, Liou LS, Gerry NP, Frampton GM, Cohen HT and Christman MF. Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data. BMC cancer. 2003; 3:31.
40. Yusenko M V, Kuiper RP, Boethe T, Ljungberg B, van Kessel AG and Kovacs G. High-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomas. BMC cancer. 2009; 9:152.
41. Li HZ, Gao Y, Zhao XL, Liu YX, Sun BC, Yang J and Yao Z. Effects of raf kinase inhibitor protein expression on metastasis and progression of human breast cancer. Mol Cancer Res. 2009; 7:832-840.
42. Langner C, Ratschek M, Rehak P, Schips L and Zigeuner R. Expression of MUC1 (EMA) and E-cadherin in renal cell carcinoma: a systematic immunohistochemical analysis of 188 cases. Mod Pathol. 2004; 17:180-8.
43. Vasselli JR, Shih JH, Iyengar SR, Maranchie J, Riss J, Worrell R, Torres-Cabala C, Tabios R, Mariotti A, Stearman R, Merino M, Walther MM, Simon R, Klausner RD and Linehan WM. Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Proc Natl Acad Sci USA. 2003; 100:6958-63.
44. Al-Mulla F, Hagan S, Al-Ali W, Jacob SP, Behbehani AI, Bitar MS, Dallol A and Kolch W. Raf kinase inhibitor protein: mechanism of loss of expression and association with genomic instability. J Clin Pathol. 2008; 61:524-9.
45. Knebelmann B, Ananth S, Cohen HT and Sukhatme VP. Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor. Cancer Res. 1998; 58:226-31.
46. Shweiki D, Itin A, Soffer D and Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992; 359:843-845.
47. Fu Z, Kitagawa Y, Shen R, Shah R, Mehra R, Rhodes D, Keller PJ, Mizokami A, Dunn R, Chinnaiyan AM, Yao Z and Keller ET. Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer. Prostate. 2006; 66:248-56.
48. Moffit JS, Boekelheide K, Sedivy JM and Klysik J. Mice lacking Raf kinase inhibitor protein-1 (RKIP-1) have altered sperm capacitation and reduced reproduction rates with a normal response to testicular injury. Mice lacking Raf kinase inhibitor protein-1 (RKIP-1) have altered sperm capacitation and reduced reproduction rates with a normal response to testicular injury. J Androl. 2007; 28:883-90.
49. Doyle B, Hagan S, Al-Mulla F, Scott L, Harden S, Paul J, Mulcahy H, Murray GI, Sheahan K, O'Sullivan J and Kolch W. Raf kinase inhibitor protein expression combined with peritoneal involvement and lymphovascular invasion predicts prognosis in Dukes' B colorectal cancer patients. Histopathology. 2013; 62:505-10.
50. Shin SY, Rath O, Choo SM, Fee F, McFerran B, Kolch W and Cho K. H. Positive-and negative-feedback regulations coordinate the dynamic behavior of the Ras-Raf-MEK-ERK signal transduction pathway. J Cell Sci. 2009; 122:425-35.
51. Moon A, Park JY, Sung JY, Park YK and Kim YW. Reduced expression of Raf-1 kinase inhibitory protein in renal cell carcinoma: a significant prognostic marker. Pathology. 2012; 44:534-9.
52. He L, Ingram A, Rybak AP and Tang D. Shank-interacting protein-like 1 promotes tumorigenesis via PTEN inhibition in human tumor cells. J Clin Invest. 2010; 120:2094-108.
53. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh FM, Lubensky I, Duan DR, Florence C, Pozzatti R, Walther MM and Bander NH, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994; 7:85-90.
54. Xie Y, Yan J, Cutz JC, Rybak AP, He L, Wei F, Kapoor A, Schmidt VA, Tao L and Tang D. IQGAP2, A candidate tumour suppressor of prostate tumorigenesis. Biochim Biophys Acta. 2012; 1822:875-884.
55. Mehta R, Kyshtoobayeva A, Kurosaki T, Small EJ, Kim H, Stroup R, McLaren CE, Li KT and Fruehauf JP. Independent association of angiogenesis index with outcome in prostate cancer. Clin Cancer Res. 2001; 7:81-88.
56. Randall LM, Monk BJ, Darcy KM, Tian C, Burger RA, Liao SY, Peters WA, Stock RJ and Fruehauf JP. Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study. Gynecol Oncol. 2009; 112:583-589.
57. Van den Hoogen C, Van der Horst G, Cheung H, Buijs JT, Lippitt JM, Guzmán-Ramírez N, Hamdy FC, Eaton CL, Thalmann GN, Cecchini MG, Pelger RC and van der Pluijm G. High aldehyde dehydrogenase activity identifies tumor-initiating and metatasis initiating cells in human prostate cancer. Cancer Res. 2010; 70:5163-73.
58. He L, Fan C, Kapoor A, Ingram AJ, Rybak AP, Austin RC, Dickhout J, Cutz JC, Scholey J and Tang D. alpha-Mannosidase 2C1 attenuates PTEN function in prostate cancer cells. Nat Commun. 2011; 2:307.